Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure by Benjamin W. Van Tassell, Justin Canada, Salvatore Carbone, Cory Trankle, Leo.

Slides:

Advertisements

Similar presentations

Dronedarone in patients with congestive heart failure: insights from ATHENA by Stefan H. Hohnloser, Harry J.G.M. Crijns, Martin van Eickels, Christophe.

Advertisements

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Randomized Trial to Assess Catheter Ablation Versus.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiopoietic Stem Cell Therapy in Heart Failure:

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiopulmonary Exercise Testing in Heart Failure.

Copyright © 2006 American Medical Association. All rights reserved.

Systolic and Diastolic Pulsus Alternans in Severe Heart Failure

Copyright © 2006 American Medical Association. All rights reserved.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm? Gerard O. Oghlakian, MD, Ilke Sipahi, MD, James.

Copyright © 2007 American Medical Association. All rights reserved.

Usefulness of Matrix Metalloproteinase-9 Plasma Levels to Identify Patients With Preserved Left Ventricular Systolic Function After Acute Myocardial Infarction.

Role of Right Ventricle and Dynamic Pulmonary Hypertension on Determining ΔVO2/ΔWork Rate FlatteningCLINICAL PERSPECTIVE by Francesco Bandera, Greta Generati,

Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men by Roberto Pedrinelli, Giulia Dell’Omo, Giuseppe Penno, Simona Bandinelli,

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Right Ventricular Failure in Idiopathic Pulmonary Arterial Hypertension Is Associated With Inefficient Myocardial Oxygen UtilizationClinical Perspective.

Plasma Vitamin C, but Not Vitamin E, Is Associated With Reduced Risk of Heart Failure in Older MenClinical Perspective by Sasiwarang Goya Wannamethee,

Noninfectious Mitral Annular Disruption

Iron, Inflammation, and Early Death in Adults With Sickle Cell DiseaseNovelty and Significance by Eduard J. van Beers, Yanqin Yang, Nalini Raghavachari,

Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing.

Choline Diet and Its Gut Microbe–Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload–Induced Heart FailureCLINICAL PERSPECTIVE by.

Site Selection and Performance in Clinical Trials

Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton,

Patent Foramen Ovale Closure in Obstructive Sleep Apnea Improves Blood Pressure and Cardiovascular FunctionNovelty and Significance by Stefano F. Rimoldi,

Box plot showing percentage change in early diastolic pulsed-Doppler mitral inflow (E)/early diastolic tissue Doppler velocity (E´) from pre– to post–balloon.

Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart FailureClinical Perspective by A. Rogier van der Velde, Lars Gullestad,

Effect of intervention on diastolic function.

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Resting Ventricular–Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection FractionCLINICAL PERSPECTIVE by Selma F. Mohammed,

Optimal Pacing for Right Ventricular and Biventricular Devices

by Peter J. Schwartz, Maria Teresa La Rovere, Gaetano M

by Iacopo Olivotto, Jennifer L

by Alexander Leaf, Christine M

Circ Cardiovasc Imaging

Pulmonary and Systemic Circulation

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Volume 10, Issue 10, Pages (October 2013)

Restrictive Mitral Annuloplasty Does Not Limit Exercise Capacity

A review of PCSK9 inhibition and its effects beyond LDL receptors

Volume 10, Issue 10, Pages (October 2013)

Figure 2 Echocardiographic methods to estimate left atrial pressure

Figure 2 Results of diastolic stress testing

Shadi Al Halabi et al. JACEP 2015;1:

Normal ranges by corrected gestational age at scan for bFFE assessment of left ventricular output (A), end-diastolic volume (B), end-systolic volume (C)

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Nat. Rev. Cardiol. doi: /nrcardio

Incremental predictive value of CR after repetitive squatting exercise and FC from cardiopulmonary testing exercise results over clinical (red) and echocardiographic.

Juan A. Crestanello, MD, Richard C. Daly, MD

Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm? Gerard O. Oghlakian, MD, Ilke Sipahi, MD, James.

Bar chart of cardiac volumes and EF in the healthy individuals, HCM LVH− patients and HCM LVH+ patients. Blue bars show the indexed diastolic volumes (EDVI.

Romain Gallet et al. BTS 2016;1:14-28

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Relationship between the change in left ventricular ejection fraction (ΔLVEF) and change in left ventricular diastolic dimension (ΔLVDd) at 4 years at.

Positive end-expiratory pressure aggravates left ventricular diastolic relaxation further in patients with pre-existing relaxation abnormality J.H. Chin,

Rick A. Nishimura et al. JACC 2014;63:e57-e185

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Unadjusted means by smoking status

John A. Sallach et al. JIMG 2009;2:

Satoru Kishi et al. JCHF 2014;2:

Pro-inflammatory biomarkers in decompensated and stable HFpEF patients

Rick A. Nishimura et al. JACC 2017;70:

Histograms of LVESVI, LVEDVI, LVMI, and 3D LVEF Tabulations of frequencies of left ventricular end-systolic volume (A), end-diastolic volume (B), mass.

Marco Guazzi et al. JACC 2017;70:

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Examples of ventilatory efficiency slope (minute ventilation (V′E)/carbon dioxide production (V′CO2) slope) in a healthy subject (green line) and a patient.

Patient selection process in the present study.

Diastolic dysfunction in sickle cell

Presentation transcript:

Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure by Benjamin W. Van Tassell, Justin Canada, Salvatore Carbone, Cory Trankle, Leo Buckley, Claudia Oddi Erdle, Nayef A. Abouzaki, Dave Dixon, Dinesh Kadariya, Sanah Christopher, Aaron Schatz, Jessica Regan, Michele Viscusi, Marco Del Buono, Ryan Melchior, Pranav Mankad, Juan Lu, Robin Sculthorpe, Giuseppe Biondi-Zoccai, Edward Lesnefsky, Ross Arena, and Antonio Abbate Circ Heart Fail Volume 10(11):e004373 November 15, 2017 Copyright © American Heart Association, Inc. All rights reserved.

Screening and enrollment of patients. Screening and enrollment of patients. CPX indicates cardiopulmonary exercise test; and CRP, C-reactive protein. Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373 Copyright © American Heart Association, Inc. All rights reserved.

Effects of treatment on peak volume of oxygen consumption (VO2) and minute ventilation-carbon dioxide production slope (VE/VCO2) slope. Effects of treatment on peak volume of oxygen consumption (VO2) and minute ventilation-carbon dioxide production slope (VE/VCO2) slope. Columns represent median values (vertical bars represent interquartile ranges). Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373 Copyright © American Heart Association, Inc. All rights reserved.

Effects of treatment on plasma C-reactive protein (CRP) levels. Effects of treatment on plasma C-reactive protein (CRP) levels. Columns represent median values (vertical bars represent interquartile ranges) using a logarithmic scale. Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373 Copyright © American Heart Association, Inc. All rights reserved.

Effects of treatment on left ventricular volume and systolic and diastolic function. Effects of treatment on left ventricular volume and systolic and diastolic function. Columns represent median values (vertical bars represent interquartile ranges). E indicates early mitral pulsed-wave Doppler flow velocity; E′, early mitral annulus tissue pulsed-wave Doppler velocity; and LVEF, left ventricular ejection fraction. Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373 Copyright © American Heart Association, Inc. All rights reserved.

Effects of treatment on quality-of-life measures. Effects of treatment on quality-of-life measures. Columns represent median values (vertical bars represent interquartile ranges). DASI indicates Duke Activity Status Index; and MLWHF, Minnesota Living With Heart Failure Questionnaire. Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373 Copyright © American Heart Association, Inc. All rights reserved.

Effects of treatment on survival free of hospital readmission for heart failure (HF). Effects of treatment on survival free of hospital readmission for heart failure (HF). The incidence of death or readmission for HF at 24 wk was 30% in the placebo group, 31% in the group treated with anakinra for 2 wk, and 6% in the group treated with anakinra 12 wk (log-rank P test P=0.10). Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373 Copyright © American Heart Association, Inc. All rights reserved.